Pharmafile Logo
Pharmafocus logo
Advanced Search

ovarian

Showing 7 posts of 7 posts found.

Pills image

Hormone replacement therapy elevates ovarian cancer risk

February 13, 2015
Research and Development, Sales and Marketing Cancer, HRT, Lancet, Oxford, oncology, ovarian

According to a new study women who undergo hormone replacement therapy nearly double their risk of developing ovarian cancer.  Findings …

News
Astrazeneca image

AstraZeneca ovarian cancer drug approved in Europe

December 18, 2014
Sales and Marketing AstraZeneca, BRCA, Cambridge, Cancer, FDA, lynparza, olaparib, ovarian

The European Commission has approved AstraZeneca’s Lynparza for the treatment of advanced BRCA-mutated ovarian cancer. Lynparza (olaparib) has been approved …

News
Astrazeneca image

AstraZeneca faces olaparib questions

June 24, 2014
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, FDA, olaparib, ovarian

AstraZeneca is facing questions from US regulators over the efficacy of one of its most promising late-stage treatments. Olaparib is …

News
votrient image

Votrient’s extended licence application ditched

April 1, 2014
Sales and Marketing EMA, Europe, GSK, ovarian, votrient kidney cancer

GlaxoSmithKline admits it is ‘disappointed’ after abandoning its attempt to extend kidney cancer drug Votrient’s licence to take in ovarian …

News
p0024

Avastin gains EU licence for ovarian cancer

January 3, 2012
Sales and Marketing Roche, avastin, ovarian

Roche’s Avastin has been granted a new European licence to treat ovarian cancer, which could help offset falling sales of …

News

Avastin study in ovarian cancer meets primary endpoint

February 25, 2010
Research and Development Cancer, avastin, ovarian

Preliminary results from a trial of Roche’s Avastin in advanced ovarian cancer suggest that the drug lengthens progression-free survival when …

News
BI Centre_03 2

Boehringer’s ovarian cancer drug enters phase III

December 18, 2009
Research and Development, Sales and Marketing Boehringer, Cancer, ovarian

Boehringer Ingelheim has started a new phase III trial for its investigational cancer drug BIBF 1120. The LUME-Ovar-1 programme will …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025